Dynavax Technologies (Dynavax Technologies) GF Value Rank : 3 (As of May. 20, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies GF Value Rank?

Dynavax Technologies has the GF Value Rank of 3.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Dynavax Technologies's GF Value Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dynavax Technologies's GF Value Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's GF Value Rank falls into.

Dynavax Technologies GF Value Rank Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (Dynavax Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Executives

Robert Janssen	officer: Chief Medical Officer and VP	C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack	officer: Senior Vice President	39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess	officer: Principal Accounting Officer	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer	officer: Co-President and Senior VP	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald	officer: SVP and CFO	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman	officer: Chief Science Officer and VP	C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach	officer: VP, CBO, and General Counsel	1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063